Volatile Organic Compounds in Cystic Fibrosis

Detection of Pulmonary Colonization in Cystic Fibrosis Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01379040

Acronym

VOCCF

Enrollment

Registered

2011-06-23

Start date

2009-08-31

Completion date

2010-12-31

Last updated

2014-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis, Pseudomonas Aeruginosa

Keywords

Cystic Fibrosis, Pseudomonas aeruginosa, Volatile Organic Compounds, Electronic nose, Gas Chromatography

Brief summary

This experiment is designed to test the effectiveness of a new electronic nose device, which allows a non-invasive breath test for markers of lower respiratory tract infection, which may predict the probability of bacterial organisms in the lower respiratory tract. It consists of: * A breath collection apparatus for collection of volatile organic compounds in breath onto a sorbent trap and Tedlar bag, as well as for the collection of a separate sample of room air. * Analysis of the volatile organic compounds in breath and room air by short acoustic wave/gas chromatography. * Interpretation of the volatile organic compounds with a proprietary algorithm in order to predict the probability of lower respiratory tract colonization and infection. This study will test the hypothesis that the investigators can identify the presence of Pseudomonas aeruginosa by sampling the head space above culture media of sputum provided by patients with cystic fibrosis. This study will test the additional hypothesis that the investigators can identify the presence of Pseudomonas aeruginosa by sampling exhaled breath from the patient providing the sputum.

Interventions

OTHERCystic Fibrosis patients

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Clinical diagnosis of Cystic Fibrosis * Must be able to give breath and sputum samples

Exclusion criteria

* Heavy smoker * Inability to regularly give breath and sputum samples * History of additional pulmonary disease

Design outcomes

Primary

Measure	Time frame	Description
Bacterial Identification	six months	Patient's provided breath samples and sputum for culture. Bacterial identification by indices was achieved

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026